Document:

exh_101.htm

Exhibit 10.1

 

 

  

  

  

 

  

  

  

Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked “***” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.

  

ATTACHMENT 2

MILESTONE AND DELIVERABLES CHART

May 7, 2015

HHSO100201500007C

	
WBS

	
Milestone

	
Deliverable

	
Success Criteria

	
Timing

	
Go/No-Go

for initiation

	
CLIN 0001 - MANUFACTURE OF CLINICAL TRIAL MATERIAL

	
1.2.1

	
Process Improvements Report

	
Report on Process Development

	
Process Developed

	
***

	  
	
1.2.2

	
Determination of Sufficient Process for Commercial Scale up

	
Evaluation report

	
BARDA approval of developed process

	
***

	
N/A

	
1.3.1

	
Manufacture ***(Batch ***)

	
***

	
Acceptable quality and yield

	
***

	
N/A

	
1.3.2

	
Manufacture ***(Batch ***)

	
***

	
Acceptable quality and yield

	
***

	
N/A

	
1.4.1

	
Manufacture cGMP BCX4430 (***campaign DS Batch ***)

	
BCX4430 DS

 

CofA,

 

	
Acceptable quality and yield

	
***

	
N/A

	
1.4.2

	
Manufacture cGMP BCX4430 (*** campaign DS Batch ***)

	
BCX4430 DS

 

CofA,

 

	
Acceptable quality and yield

	
***

	
N/A

	
1.4.3

	
Prepare a Campaign Summary Reports

	
Campaign Reports (DS Batches ***)

	
Completion of DS Campaigns

	
***

	
N/A

	
1.4.4

	
Drug substance stability study

	
Initial Report on stability activities

	
Stability data

	
***

	  
	
1.5

	
Drug Product Development

	
DP Process Development Report (WBS 1.5.4)

 

Pre-formulation and Physicochemical Report (WBS1.5.5)

 

Extractable/Leachable Report (WBS 1.5.7)

 

 

	
Completion of Studies

	
***

	
N/A

	
1.5.8

	
Excipient Compatibility Report for IV Formulation

	
Compatibility Report

	
IV formulation completed

	
***

	  
	
1.6.1

	
Manufacture cGMP DP (CTM Batch *** ***)

	
BCX4430 DP

 

CofA,

	
Acceptable quality and yield

	
***

	
Accepted GMP DS

	
1.6.2

	
Manufacture cGMP DP (CTM Batch *** ***)

	
BCX4430 DP

 

CofA,

	
Acceptable quality and yield

	
***

	
Accepted GMP DS

 

  

  

  

Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked “***” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.

 

	
1.6.3

	
Prepare a Campaign Summary Reports

	
Campaign Reports (CTM Batches ***)

	
Completion of DP Campaigns

	
***

	
N/A

	
1.6.4

	
Drug Product stability study

	
Initial Report on stability activities

	
Stability Data

	
***

	  
	
1.6.5

	
Comparability Study

	
Comparability Protocol and Report

	
Completion of DS and DP Campaigns

	
***

	  
	
1.7.1

	
Manufacture cGMP BCX4340 (*** campaign DS Batch ***)

	
BCX4430 DS

 

CofA

	
Acceptable DS process

	
***

	
N/A

	
1.7.2

	
Prepare a Campaign Summary Report

	
Campaign Reports (DS Batch***)

	
Completion of DS Campaign

	
***

	
N/A

	
1.7.2

	
Manufacture cGMP DP (CTM Batch *** ***)

	
BCX4430 DP

 

CofA,

	
Acceptable quality and yield

	
***

	
Accepted GMP DS

	
1.7.4

	
Prepare a Campaign Summary Report

	
Campaign Report (CTM Batches ***)

	
Completion of DS Campaigns

	
***

	
N/A

	
1.7.5

	
Drug Substance and Drug Product stability study

	
Initial report on stability activities

	
Stability Data

	
***

	
Manufacture of 1.7.1 drug substance and 1.7.2 drug product

	
1.7.6

	
Comparability Study

	
Comparability Protocol and Report

	
Comparable DS and DP profiles

	
***

	
N/A

	
CLIN 0002 – COMMERCIAL SCALE UP AND NDA REGISTRATION BATCHES

Go/No Go Criteria to Initiate: WBS 1.2.2 BARDA approval of process developed

 

	
2.2

	
Drug Substance Process Scale-up

	
Process Development Report (WBS 2.2.4)

	
Selection of the optimized manufacturing process

	
***

	
*** process

	
2.3.1

 

	
Manufacture BCX4340 DS (DS Registration Batch ***)

	
BCX4430 Registration

DS

 

CofA

	
Acceptable quality and yield

	
***

	
*** process

	
2.3.2

 

	
Manufacture BCX4340 DS (DS Registration Batch ***)

	
BCX4430 Registration DS

 

CofA,

	
Acceptable quality and yield

	
***

	
*** process

	
2.3.3

 

	
Manufacture BCX4340 DS (DS Registration Batch ***)

	
BCX4430 Registration DS

 

CofA,

	
Acceptable quality and yield

	
***

	
*** process

	
2.3.4

	
Prepare a Campaign Summary Report

	
Campaign Reports (DS Batches ***)

	
Completion of DS Campaign

	
***

	
N/A

	
2.4.1

 

	
Manufacture BCX4430 DP (DP Registration Batch ***)

	
BCX4430 DP

 

CofA,

	
Acceptable quality and yield

	
***

	
Accepted GMP DS

 

  

  

  

Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked “***” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.

 

	
2.4.2

 

	
Manufacture BCX4430 DP (DP Registration Batch ***)

	
BCX4430 DP

 

CofA,

	
Acceptable quality and yield

	
***

	
Accepted GMP DS

	
2.4.3

 

	
Manufacture BCX4430 DP (DP Registration Batch ***)

	
BCX4430 DP

 

CofA,

	
Acceptable quality and yield

	
***

	
Accepted GMP DS

	
2.4.4

	
Prepare a Campaign Summary Report

	
Campaign Report (CTM Registration Batches ***)

	
Completion of DS Campaigns

	
***

	
N/A

	
2.5

	
Drug substance and Drug Product stability study

	
Report on stability activities

	
Stability Data

	
***

	  
	
2.6

	
Comparability Study

	
Comparability Protocol and Report

	
Comparable DS and DP profiles

	
***

	
Accepted GMP DS

	
CLIN 0003 – NONCLINICAL NDA-ENABLING TOXICOLOGY - IM

Go/No Go Criteria to Initiate: WBS 1.4.1 Completion of Manufacture cGMP BCX4430 (*** campaign DS Batch ***)

	
3.1.1

	
Complete GLP *** IM Tox Study - ***

	
Study Report

	
Established NOAEL

	
***

	
Drug Substance confirming to release criteria

	
3.1.2

	
Complete GLP *** IM Tox Study - ***

	
Study Report

	
Established NOAEL

	
***

	
Drug Substance confirming to release criteria

	
3.2.1

	
Conduct *** assessment in *** and ***

	
Study Report

	
No significant findings

	
***

	
N/A

	
3.2.2

	
Conduct *** Dose Range Finding Studies in the ***

	
Study Report

	
No significant findings

	
***

	
N/A

	
3.2.3

	
Conduct Definitive *** toxicology in the ***

	
Study Report

	
No significant findings

	
***

	
N/A

	
3.2.4

	
Conduct *** toxicology ***

	
Study Report

	
No significant findings

	
***

	
N/A

	
3.3.1

	
Conduct Radiolabeled ADME study - ***

	
Study Report

	
Characterize drug disposition

	
***

	
Acceptable Radiolabel Material

	
3.3.2

	
Conduct Radiolabeled ADME – ***

 

	
Study Report

	
Characterize drug disposition

	
***

	
Acceptable Radiolabel Material

	
CLIN 0004 – IN VITRO EXPERIMENTS – IV

Go/No Go to Initiate: WBS 1.5.8 Completion of Excipient compatibility studies for IV formulation

	
4.1.

	
Conduct *** Test – IV

	
Study Report

	
No effect on ***

	
***

	
IV formulation WBS 1.5.8

	
4.2.

	
Conduct *** Test – IV

	
Study Report

	
No effect on ***

	
***

	
N/A

 

  

  

  

Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked “***” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.

 

	
4.3

	
*** IV experiments

	
Study report on all *** assays with recommendation to proceed CLIN0005

	
No toxicology ***

	
***

	  
	
CLIN 0005 – NONCLINICAL NDA-ENABLING TOXICOLOGY – IV

Go/No Go to Initiate: WBS 4.3 Completion of *** IV toxicology studies

	
5.1.1

	
Complete GLP *** IV Tox Study - ***

	
Study Report

	
Established NOAEL

	
***

	
Drug Substance confirming to release criteria

	
5.1.2

	
Complete GLP ***IV Tox Study - ***

	
Study Report

	
Established NOAEL

	
***

	
Drug Substance confirming to release criteria

	
5.2.1

	
Conduct *** assessment in ***

	
Study Report

	
No significant findings

	
***

	
N/A

	
5.2.2

	
Conduct *** Dose Range Finding Studies in the ***

	
Study Report

	
No significant findings

	
***

	
N/A

	
5.2.3

	
Conduct Definitive *** toxicology in the ***

	
Study Report

	
No significant findings

	
***

	
N/A

	
5.2.4

	
Conduct *** toxicology ***

	
Study Report

	
No significant findings

	
***

	
N/Aexh_106.htm

Exhibit 10.6

 

 

NOVATION AGREEMENT

 

PARTIES

 

Albert Einstein College of Medicine of Yeshiva University, a Division of Yeshiva University, of 1300 Morris Park Ave, Bronx, NY 10461,United States of America (AECOM); BioCryst Pharmaceuticals Inc of 4505 Emperor Blvd, Suite 200, Durham, NC27703, United States of America (BioCryst); Mundipharma International Corporation Limited (the permitted assignee of Mundipharma International Holdings Limited) of Mundipharma House, 14 Par-la Ville Road, Hamilton, Bermuda HMJX (Mundipharma), (each a Continuing Party and collectively, the Continuing Parties);

 

and

 

Callaghan Innovation Research Limited (formerly called Industrial Research Limited) registered in New Zealand under number 545472 (Retiring Party);

 

and

 

Victoria Link Limited, a wholly owned subsidiary of Victoria University of Wellington, registered in New Zealand under company number 540316 (Substitute Party);

 

together referred to as the Parties.

 

BACKGROUND

 

	
A.

	
Callaghan Innovation Research Limited hastransferred its Carbohydrate Chemistry Research Team and related intellectual property to Victoria Link Limited and agreements exist between Callaghan Innovation Research Limited and Victoria University of Wellington.

 

	
B.

	
Albert Einstein College of Medicine of Yeshiva University, a Division of Yeshiva University, BioCryst Pharmaceuticals Inc, Mundipharma International Corporation Limited and Callaghan Innovation Research Limitedare parties to the Novated Contracts (as defined below).

 

	
C.

	
The Parties have agreed to release and discharge:

 

	
  

	
(i) Callaghan Innovation Research Limited from the obligations and liabilities of Callaghan Innovation Research Limited to the Continuing Parties under the Novated Contracts on the condition that Victoria Link Limited agrees to assume each and every obligation and liability of Callaghan Innovation Research Limited to the Continuing Parties under the Novated Contracts and

 

	
  

	
(ii) The Continuing Parties from their obligations and liabilities to the Retiring Party

 

	
  

	
as of the Effective Date in accordance with the terms and conditions set forth herein.

 

  

-1-

  

IT IS AGREED AS FOLLOWS

 

	1. 	
DEFINITIONS AND INTERPRETATION

 

In this Agreement:

 

	
1.1  

	
Agreement means this Agreement and all its schedules and attachments.

 

	
1.2  

	
Continuing Parties means AECOM, BioCryst and Mundipharma, each of whom will continue to be bound under the Novated Contracts.

 

	
1.3  

	
Effective Date means 6 January 2014.

 

	
1.4  

	
Novated Contracts means the contract or contracts marked and annexed as Schedule 1 to this Agreement, including, but not limited to, the Insolvency Letter dated February 1, 2006 (as amended pursuant to the First Amendment to Insolvency Letter dated November 11, 2011) (the “Insolvency Letter”).

 

	
1.5  

	
Retiring Party means Callaghan Innovation Research Limited, who is releasing and discharging the obligations and liabilities under the Novated Contracts to the Substitute Party in accordance with the terms and conditions set forth herein.

 

	
1.6  

	
Substitute Party means Victoria Link Limited who is assuming the obligations and liabilities of the Retiring Party under the Novated Contracts in accordance with the terms and conditions set forth herein.

 

	
1.7  

	
Working Day means any day on which registered banks are open for general banking business in Wellington, other than a Saturday, Sunday, public holiday in Wellington, New Zealand, or a day on which Victoria University of Wellington is closed (as identified in its calendar).

 

	2. 	

NOVATION

 

	
2.1  

	
With effect from the Effective Date, and subject to clauses 3.1 and 7.1, the Parties novate the Novated Contracts and the Substitute Party undertakes to the Continuing Parties that it will:

 

	 	
a.

	
replace the Retiring Party and be bound by the Novated Contracts; and

 

	 	
b.

	
discharge all of the obligations of the Retiring Party under the Novated Contracts and observe all the provisions of the Novated Contracts to the extent they ariseon or after the Effective Date; and

 

	 	
c.

	
be liable to the Continuing Parties for the performance of any obligations on the part of the Retiring Party under or in connection with the Novated Contractson or after the Effective Date.

 

  

-2-

  

	3. 	

RELEASE OF RETIRING PARTY’S OBLIGATIONS

 

	
3.1  

	
In consideration of the undertaking by the Substitute Party under clause 2.1 above, and subject to clause 7.1 and 7.2, with effect fromthe Effective Date the Continuing Parties release and discharge the Retiring Party from further performance of its obligations under the Novated Contracts and from all liabilities, claims and demands of any kind arising under or in connection with the Novated Contracts on or after the Effective Date but not prior to the Effective Date. The Retiring Party will continue to be liable to the Continuing Parties for all of its acts and omissions which occurred before the Effective Date as if this Agreement had never been executed.

 

	4. 	

CONTINUING PARTIES’ OBLIGATIONS

 

	
4.1  

	
Each Continuing Party undertakes to the Substitute Party that it will with effect from the Effective Date:

 

	 	
a.  

	
discharge all of its respective obligations under the Novated Contracts and observe all the provisions of the Novated Contracts; and

 

	 	
b.  

	
be liable to the Substitute Party for the performance of its respective obligations under or in connection with the Novated Contracts arising on or after the Effective Date.

 

	5. 	

CESSATION OF RETIRING PARTY’S RIGHTS

 

	
5.1  

	
Without prejudice to clauses 2.1 and 4.1 above, with effect fromthe Effective Date, the Retiring Party:

 

	 	
a.

	
shall cease to have any rights under the Novated Contracts in respect of any acts or omissions of the Continuing Partieson or after the Effective Date arising under or in connection with the Novated Contracts; and

 

	 	
b.

	
shall cease to be a third party beneficiary pursuant to section 13.6 (Pre-Existing Third Party License) of the Amended and Restated Development and License Agreement dated November 11th, 2011 by and Between BioCryst and MundiPharma (the “2011 DLA”) and shall cease to be entitled to enforce BioCryst’s rights thereunder in respect of anyacts or omissions of Mundipharma on or after the Effective Date arising under or in connection with the 2011 DLA.

 

	
  

	
Accordingly:

 

	
a.

	
the Retiring Party releases and discharges each Continuing Party from further performance of its respective obligations underthe Novated Contracts and from all liabilities, claims and demands of any kind arising under or in connection with the Novated Contracts on or after the Effective Date; and

 

	
b.

	
the Retiring Party releases and discharges Mundipharma from further performance of its obligations under the 2011 DLA and from all liabilities, claims and demands of any kind arising under or in connection with the 2011 DLA on or after the Effective Date.

 

  

-3-

  

 

	6. 	

WARRANTIES AND ACKNOWLEDGEMENT

 

	
6.1  

	
Each Continuing Party and the Retiring Party warrants to the Substituting Party that as at the Effective Date:

 

	 	
a.

	
the Novated Contracts constitute the entire agreement between the Continuing Party and the Retiring Party relating to the subject matter of the Novated Contracts with the understanding that a separate novation addresses certain additional agreements entered into by the AECOM, BioCryst, Substitute Party and Retiring Party; and

 

	 	
b.  

	
so far as it is aware neither the Retiring Party nor the Continuing Parties is in default under the Novated Contracts which could lead to termination of the Novated Contracts.

 

	
6.2  

	
The Continuing Parties and the Substitute Party acknowledge and agree that the Novated Contracts continue in full force and effect on and after the Effective Date in accordance with their terms as novated by this Agreement.

 

	
6.3  

	
The Retiring Party and the Substitute Party each warrant to each Continuing Party that

 

	 	
a.  

	
they have completed the appropriate documents and transfer so that each Continuing Partyis released of obligations from the Retiring Party for obligations going forward on and after the Effective Date of this Agreement; Contracts; and

 

	
  

	
b.

	
the Novated Contracts as set forth in Schedule I make reference to each and every agreement entered into by the Continuing Parties and the Retiring Party (subject to Section 6.1(a) of this Agreement) such that the Continuing Parties will enjoy the same rights and benenfits and assume the same obligations and liabilities as would be the case if the Continuing Parties had not entered into this Agreement.

 

	
6.4

	
The Substitute Party warrants to each Continuing Party that:

 

	
  

	
a.

	
It is a viable going concern and has the personnel, expertise and resources to carry out it obligations and responsibilities under the Novated Contracts and has the financial resources to assume any and all liabilities under the Novated Contracts; and

 

	 	
b.  

	
the Substitute Party has the right to grant the rights and licences under the Novated Contracts, including the right to grant the rights and licensesunder the “Agreement Patents” (as defined in the Insolvency Letter).

 

	7. 	

CONFIDENTIALITY

 

	
7.1  

	
Pursuant to section 13.6 of the 2011 DLA, Mundipharma grants its consent for BioCryst to disclose Mundipharma’s Confidential Information (as defined in the 2011 DLA) to the Substitute Party. The Continuing Parties and the Substitute Party acknowledge and agree that such disclosure of Mundipharma’s Confidential Information shall be deemed to be “Licensee Confidential Information” subject to paragraph 5.03 of the AECOM/IRL License Agreement dated June 27, 2000 (as amended) (the 2000 LA).

 

  

-4-

  

 

	
7.2  

	
Notwithstanding the novation effected by this Agreement, the Retiring Party will continue to be bound by any obligations of confidentiality and non-disclosure that the Retiring Party would have been under had the Retiring Party continued to be a Party of theNovated Contracts, including any such obligations pursuant to the 2000 LA.

 

	8. 	

ASSIGNMENT AND AMENDMENT

 

	
8.1  

	
Without the prior written approval of the Continuing Parties and the Substitute Party, which approval shall not be unreasonably withheld, no Continuing Party or Substitute Party will assign this Agreement except to a successor in title of by merger or sale of all or substantially all of such Party’s business to which this Agreement relates.

 

	
8.2  

	
No amendment to this Agreement shall be binding unless in writing and agreed to and signed by the respective Parties.

 

	9. 	

ENTIRE AGREEMENT

 

	
9.1  

	
This Agreement, together with any documents referred to in it, constitutes the whole agreement between the Parties relating to its subject matter and supersedes and extinguishes any prior drafts, agreements, undertakings, representations, warranties and arrangements of any nature, whether in writing or oral, relating to such subject matter.

 

	10. 	

NOTICES

 

	
10.1  

	
Any communication including any notice, consent, information, application or request that must or may be given or made to a Party under this Agreement, can be:

 

	 	
a.  

	
in writing and sent to the physical address of the Party as listed in the Novated Contracts, or, with respect to the Retiring Party and the Substitute Party, as listedat clause 10.3, and marked for the attention of the person or office holder (if any) from time to time designated for that purpose by the relevant Party;

 

	 	
b.  

	
in writing and sent to the email address of the Party as listed at clause 10.3 or of the person or office holder (if any) from time to time designated for that purpose by the relevant Party and followed by a hard copy sent by post in accordance with clause 10.1(a);

 

	 	
c.  

	
in writing and delivered in person to the physical address of the Party as listed at clause 10.3, and marked for the attention of the person or office holder (if any) from time to time designated for that purpose by the relevant Party.

 

	
10.2  

	
A communication including any notice, consent, information, application or request will be deemed to be received:

 

	 	
a.  

	
by post, on the third Working Day after posting;

 

	 	
b.  

	
by email,

 

  

-5-

  

 

	 	
i.

	
where it is transmitted on a Working Day, on the Working Day on which it is transmitted and at the time the email enters the recipient’s information system as evidenced by a delivery receipt requested by the sender and it is not returned undelivered as an error; or

 

	 	
ii.

	
where it is transmitted on a day other than a Working Day, at 9:00 a.m. on the subsequent Working Day after the date of transmission;

 

	 	
c.  

	
by personal delivery, at the date and time it was delivered.

 

	
10.3  

	
The physical address, email address and relevant person or office holder of the Retiring Party and the Substitute Party are set out below:

 

	
The University

	  	 	  
	
Name:

	 	
Vice Provost Research and Chairman of VicLink

	
Address:

	 	
Victoria University of Wellington

	  	 	
PO Box 600

	  	 	
Wellington 6140

	  	 	  
	
Email address:

	 	
kate.mcgrath@vuw.ac.nz

	  	 	  
	
With a copy to:

	 	
In-house Solicitor

	  	 	
Victoria University of Wellington

	  	 	
PO Box 600

	  	 	
Wellington 6140

	  	 	
simon.johnson@vuw.ac.nz

	  	 	  
	
Callaghan Innovation Research Limited

	  	 	  
	
Name:

	 	
General Manager Research and Technical Services

	
Address:

	 	
Callaghan Innovation

	  	 	
PO Box 31310

	  	 	
Lower Hutt 5040

	
Email address:

	 	
Richard.Templer@callaghaninnovation.govt.nz

	  	 	  
	
With a copy to:

	 	
Solicitor

	  	 	
Callaghan Innovation

	  	 	
PO Box 31310

	  	 	
Lower Hutt 5040

	  	 	
Pauline.Zumbach@callaghaninnovation.govt.nz

 

 

	11. 	

GENERAL

 

	
11.1  

	
A failure by a Party to enforce a provision of this Agreement will not constitute a waiver of any right to future enforcement of that or any other provision.

 

  

-6-

  

 

	
11.2  

	
If any part of this Agreement is unenforceable, invalid or illegal, the other terms will remain in force.

 

	
11.3  

	
This Agreement may be signed in counterparts, including by facsimile or email, all of which, when taken together, will constitute one and the same document.

 

	
11.4  

	
This Agreement will be governed and construed under the laws of New York, without regard to its choice of law principles.The Parties hereby irrevocably submit to the jurisdiction of the courts located in the County and State of New York.

 

 

 

Executed as an Agreement:

 

	
Signed by Albert Einstein College of Medicine of Yeshiva University, a Division of Yeshiva University:

	  	  
	 	 
	
/s/ John L. Harb

	  
	
Signature

	  
	  	  
	
John L. Harb

	  
	
Name of authorised signatory

	  	  
	
Assistant Dean

	  
	
Scientific Operations

	  
	
Position of authorised signatory

	  	  
	
Date: 6 May 2015

 

  

-7-

  

 

	
Signed by BioCryst Pharmaceuticals Inc:

	 	 
	 	 
	
/s/ Alane Barnes

	 
	
Signature

	 
	 	 
	
Alane Barnes

	 
	
Name of authorised signatory

	 	 
	

VP, General Counsel & Corporate Secretary

	 
	
Position of authorised signatory

	 	 
	
Date: 18 May 2015

 

 

	
Signed by Mundipharma International Corporation Limited:

	 	 
	 	 
	
/s/ Douglas Docherty 

	 
	
Signature

	 
	 	 
	
Douglas Docherty 

	 
	
Name of authorised signatory

	 	 
	
Director / General Manager 

	 
	
Position of authorised signatory

	 	 
	
Date: 6 May 2015

 

  

-8-

  

 

 

	
Signed by Callaghan Innovation Research Limited:

	  	  	  
	  	  	  	  	  
	 	 	 	 	 
	
/s/ Monica Roach

	  	  	  	  
	
Witness Signature

	  	
/s/ Richard Templer

	  
	  	  	  	
Signature of Attorney

	  	  	  	  	  
	
Monica Roach

	  	  	
Name: Richard Templer

	  
	
Name of Witness

	  	
Position: General Manager Research and Technical Services

	  	  	  	  	  
	  	  	  	  	  
	
Wellington, New Zealand

	  	  	 	  
	
Location of Witness

	  	  	  
	  	  	  	Date: 1 May 2015	  
	  	  	  	  	  
	
Solicitor

	  	  	  	  
	
Occupation of Witness

	  	  	  
	 	 	 	 

 

 

	
Signed by Victoria Link Limited:

	  	  	  	  
	  	  	  	  	  
	 	 	 	 	 
	
/s/ Simone Smith

	  	  	
/s/ G.A. Todd

	  
	
Witness Signature

	  	
Signature

	  
	  	  	  	  	  
	
Simone Smith

	  	  	
G.A. Todd

	  
	
Name of Witness

	  	  	
Name of authorised signatory

	 	  	  	  
	Wellington, New Zealand	  	  	
Managing Director

	  
	
Location of Witness

	  	  	
Position of authorised signatory

	 	  	  	  	  
	
Administration Manager

	 	  	 	  
	
Occupation of Witness

	  	  	  	  
	 	 	 	Date: 6 May 2015	 
	 	 	 	 

 

 

  

-9-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00248-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00248-of-00352.parquet"}]]